Digoxin-Mediated Inhibition of Potential Hypoxia-Related Angiogenic Repair in Modulated Electro-Hyperthermia (mEHT)-Treated Murine Triple-Negative Breast Cancer Model
ACS Pharmacology & Translational Science · 09.02.2024 · 7 (2) · 456-466
DOI: 10.1021/acsptsci.3c00296 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 09.01.2024. Verfasst von Syeda Mahak Zahra Bokhari und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Semmelweis University, Üllői út 26, Budapest 1085, Hungary. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tempus K??zalap??tv??ny, Nemzeti Kutat??si Fejleszt??si ??s Innov??ci??s Hivatal, Semmelweis Egyetem.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer type with no targeted therapy and hence limited treatment options. Modulated electrohyperthermia (mEHT) is a novel complementary therapy where a 13.56 MHz radiofrequency current targets cancer cells selectively, inducing tumor damage by thermal and electromagnetic effects. We observed severe vascular damage in mEHT-treated tumors and investigated the potential synergism between mEHT and inhibition of tumor vasculature recovery in our TNBC mouse model. 4T1/4T07 isografts were orthotopically inoculated and treated three to five times with mEHT. mEHT induced vascular damage 4-12 h after treatment, leading to tissue hypoxia detected at 24 h. Hypoxia in treated tumors induced an angiogenic recovery 24 h after the last treatment. Administration of the cardiac glycoside digoxin with the potential hypoxia-inducible factor 1-α (HIF1-α) and angiogenesis inhibitory effects could synergistically augment mEHT-mediated tumor damage and reduce tissue hypoxia signaling and consequent vascular recovery in mEHT-treated TNBC tumors. Conclusively, repeated mEHT induced vascular damage and hypoxic stress in TNBC that promoted vascular recovery. Inhibiting this hypoxic stress signaling enhanced the effectiveness of mEHT and may potentially enhance other forms of cancer treatment.
Autor:innen und Institutionen
- Institute of Translational Medicine, Semmelweis University, Üllői út 26, Budapest 1085, Hungary.
- Cerebrovascular and Neurocognitive Disorders Research Group, Eötvös, Loránd Research Network and Semmelweis University (ELKH-SE), Tűzoltó utca 37-47, Budapest 1094, Hungary.
ORCID-Profile: Syeda Mahak Zahra Bokhari, Kenan Aloss, Péter Hamar
Förderung
- Tempus K??zalap??tv??ny
- Nemzeti Kutat??si Fejleszt??si ??s Innov??ci??s Hivatal
- Semmelweis Egyetem
Zitieren
APA
Bokhari, S. M. Z., Aloss, K., Leroy Viana, P. H., Schvarcz, C. A., Besztercei, B., Giunashvili, N., Bócsi, D., Koós, Z., Balogh, A., Benyó, Z., & Hamar, P. (2024). Digoxin-Mediated Inhibition of Potential Hypoxia-Related Angiogenic Repair in Modulated Electro-Hyperthermia (mEHT)-Treated Murine Triple-Negative Breast Cancer Model. ACS Pharmacology & Translational Science, 7(2), 456-466. https://doi.org/10.1021/acsptsci.3c00296
Vancouver
Bokhari SMZ, Aloss K, Leroy Viana PH, Schvarcz CA, Besztercei B, Giunashvili N, et al. Digoxin-Mediated Inhibition of Potential Hypoxia-Related Angiogenic Repair in Modulated Electro-Hyperthermia (mEHT)-Treated Murine Triple-Negative Breast Cancer Model. ACS Pharmacology & Translational Science. 2024;7(2):456-466. doi:10.1021/acsptsci.3c00296
BibTeX
@article{Bokhari2024,
author = {Bokhari, Syeda Mahak Zahra and Aloss, Kenan and Leroy Viana, Pedro Henrique and Schvarcz, Csaba András and Besztercei, Balázs and Giunashvili, Nino and Bócsi, Dániel and Koós, Zoltán and Balogh, Andrea and Benyó, Zoltán and Hamar, Péter},
title = {Digoxin-Mediated Inhibition of Potential Hypoxia-Related Angiogenic Repair in Modulated Electro-Hyperthermia (mEHT)-Treated Murine Triple-Negative Breast Cancer Model},
journal = {ACS Pharmacology & Translational Science},
year = {2024},
volume = {7},
number = {2},
pages = {456--466},
doi = {10.1021/acsptsci.3c00296}
}
EUVIMED